Steward Health Care System

Return to Results

Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)

new search

Trial Conditions
  • Psoriasis
What is the purpose of this trial?

Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.

Date & Status

Terminated

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Both

Eligibility

Inclusion Criteria:

- Psoriasis patients who are prescribed alefacept consistent with product labeling are
eligible for enrollment.

Gender: Both
Steward Physician(s)
  • Vice President Medical Affairs
Trial Interventions
Drug
  • Alefacept exposure
Physician Researcher

Investigator Name:

  • Vice President Medical Affairs

Other Information

Sponsor: Astellas Pharma Inc
Phase: Phase 4
Trial ID: NCT00454701
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions